Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Cited by (531)

Items 201–300 of 531

1. Lipid-Based Delivery Systems in Development of Genetic and Subunit Vaccines
   Azam Bolhassani · 2022 · Molecular Biotechnology
2. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition
   Röltgen, Katharina, Nielsen, Sandra C. A., Arunachalam, Prabhu S., Yang, Fan, Hoh, Ramona A., Wirz, Oliver F., Lee, Alexandra S., Gao, Fei, Mallajosyula, Vamsee, Li, Chunfeng et al. · 2021
3. Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy
   Yu Huang, Hui Fan, Huihui Ti · 2024 · Asian Journal of Pharmaceutical Sciences
4. Strategies for inducing effective neutralizing antibody responses against HIV-1
   Iván del Moral-Sánchez, Kwinten Sliepen · 2019 · Expert Review of Vaccines
5. mRNA-Based Vaccines and Mode of Action
   Janina Gergen, Benjamin Petsch · 2020 · Current topics in microbiology and immunology
6. An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo
   M. M. Rahman, Nan Zhou, Jian‐Dong Huang · 2021 · Vaccines
7. Polymeric Nanoparticles for Inhaled Vaccines
   Nusaiba K. Al‐Nemrawi, Ruba S. Darweesh, Lubna A. Alshriem, Farah S. Al-Qawasmi, Sereen O. Emran, Areej S. Khafajah, Muna Abu‐Dalo · 2022 · Polymers
8. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals
   Lederer, Katlyn, Parvathaneni, Kalpana, Painter, Mark M., Bettini, Emily, Agarwal, Divyansh, Lundgreen, Kendall A., Weirick, Madison, Goel, Rishi R., Xu, Xiaoming, Drapeau, Elizabeth M. et al. · 2021
9. An old problem with new solutions: Strategies to improve vaccine efficacy in the elderly
   Matthew R. Bell, Michele A. Kutzler · 2022 · Advanced Drug Delivery Reviews
10. A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection
    Binfan Chen, Yuchen Chen, Jian Li, Chunyu Wang, Wenping Song, Yumei Wen, Jinzhong Lin, Yanling Wu, Tianlei Ying · 2022 · mBio
11. Nucleic acid delivery and nanoparticle design for COVID vaccines
    Jason L. Andresen, Owen S. Fenton · 2021 · MRS Bulletin
12. Reducing cell intrinsic immunity to mRNA vaccine alters adaptive immune responses in mice
    Ziyin Wang, Egon J. Jacobus, David C. Stirling, Stefanie A. Krumm, Katie E. Flight, Robert F. Cunliffe, Jonathan Mottl, Charanjit Singh, Lucy G. Mosscrop, Letícia Aragão Santiago et al. · 2023 · Molecular Therapy — Nucleic Acids
13. mRNA Vaccine Nanoplatforms and Innate Immunity
    Lai Wei, Chunhong Dong, Wandi Zhu, Bao‐Zhong Wang · 2024 · Viruses
14. mRNA-based HIV-1 vaccines
    Shamim Ahmed, Alon Herschhorn · 2024 · Clinical Microbiology Reviews
15. Poly(β-amino ester) polymer library with monomer variation for mRNA delivery
    Hong Lyun Kim, Gurusamy Saravanakumar, Seowon Lee, Subin Jang, Seonwoo Kang, Mihyeon Park, Sivasangu Sobha, S. Y. Park, Soo-Min Kim, Jung-Ah Lee et al. · 2024 · Biomaterials
16. mRNA therapeutics: Transforming medicine through innovation in design, delivery, and disease treatment
    Mark Akinola Ige, Xiaohu Ren, Yang Yang, Haiping Zhang, Chenguang Shen, Yushan Jiang, Junxin Li, Xiaochun Wan · 2025 · Molecular Therapy — Nucleic Acids
17. T-follicular helper cells in malaria infection and roles in antibody induction
    Megan S. F. Soon, Mayimuna Nalubega, Michelle J. Boyle · 2021 · Oxford Open Immunology
18. Functions and therapeutic applications of pseudouridylation
    Nan Luo, Qiang Huang, Mei‐Ling Zhang, Chengqi Yi · 2025 · Nature Reviews Molecular Cell Biology
19. Protein-Based Nanoparticle Vaccines for SARS-CoV-2
    Hyo-Dong Sung, Nayeon Kim, Yeram Lee, Eun Jung Lee · 2021 · International Journal of Molecular Sciences
20. Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
    Cong Liu, Nino Rcheulishvili, Zhigao Shen, Dimitri Papukashvili, Fengfei Xie, Ziqian Wang, Xingyun Wang, Yunjiao He, Peng George Wang · 2022 · Pharmaceutics
21. Application of mRNA Technology in Cancer Therapeutics
    Yeşim Eralp · 2022 · Vaccines
22. SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
    Raju Sunagar, Amit Singh, Sudeep Kumar · 2023 · Vaccines
23. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
    Yingqi Jin, Chen Hou, Yonghao Li, Kang Zheng, Chuan Wang · 2022 · Frontiers in Immunology
24. Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine
    Ivan V. Kuzmin, Rubén Soto-Acosta, Layne Pruitt, Perry T. Wasdin, Kritika Kedarinath, Keziah R. Hernandez, Kristyn A. Gonzales, Kharighan Hill, Nicole G. Weidner, Chad E. Mire et al. · 2024 · Nature Communications
25. In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
    Ignasi Esteban, Carmen Pastor-Quiñones, Lorena Usero, Montserrat Plana, Felipe García, Lorna Leal · 2021 · Viruses
26. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination
    Zekun Mu, Barton F. Haynes, Derek W. Cain · 2021 · Current Opinion in Virology
27. Emerging Progress of RNA-Based Antitumor Therapeutics
    Jiayan Fu, Haiyang Dong, Jian Wu, Yongfeng Jin · 2023 · International Journal of Biological Sciences
28. Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response
    William R. Dowell, Jacob S. Dearborn, Sylvester Languon, Zachary D. Miller, Tylar Kirch, Stephen Paige, Olivia Garvin, Lily Kjendal, Ethan Harby, Adam B. Zuchowski et al. · 2024 · The Journal of Immunology
29. Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
    Rose Razavi, Michael Kegel, Jenna Muscat-Rivera, Drew Weissman, Jilian R. Melamed · 2025 · Molecular Therapy — Methods & Clinical Development
30. Bispecific antibodies: Potential immunotherapies for HIV treatment
    Giulia Fabozzi, Amarendra Pegu, Richard A. Koup, Constantinos Petrovas · 2018 · Methods
31. COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics
    Saman Zafar, Muhammad Sohail Arshad, Sameen Fatima, Amna Alrasheed Abuzaid Ali, Aliyah Zaman, Elshaimaa Sayed, Ming‐Wei Chang, Zeeshan Ahmad · 2020 · Pharmaceutics
32. Analytical techniques currently used in the pharmaceutical industry for the quality control of RNA-based therapeutics and ongoing developments
    Alice Demelenne, Anne‐Catherine Servais, Jacques Crommen, Marianne Fillet · 2021 · Journal of Chromatography A
33. Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19
    Kaavya Narasimhalu, Wai Ching Lee, Parag Ratnakar Salkade, Deidre Anne De Silva · 2021 · BMJ Case Reports
34. Nanoparticle-based delivery platforms for mRNA vaccine development
    Sezer Okay, Öznur Özge Özcan, Mesut Karahan · 2020 · AIMS Biophysics
35. Advancing mRNA Therapeutics: The Role and Future of Nanoparticle Delivery Systems
    Jiaxuan Li, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun · 2024 · Molecular Pharmaceutics
36. A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice
    Jie Liu, Jie Sun, Xue Ding, Wenhao Liu, Yipeng Wang, Zihan Wang, Hanyu Peng, Yong Zhang, Weiheng Su, Chunlai Jiang · 2024 · Emerging Microbes & Infections
37. Specific Protein Antigen Delivery to Human Langerhans Cells in Intact Skin
    Mareike Rentzsch, Robert Wawrzinek, Claudia Zelle‐Rieser, Helen Strandt, Lydia Bellmann, Felix F. Fuchsberger, Jessica Schulze, Jil A. Busmann, Juliane Rademacher, Stephan Sigl et al. · 2021 · Frontiers in Immunology
38. mRNA vaccines offer hope for HIV
    Lynn Morris · 2021 · Nature Medicine
39. The mRNA vaccine, a swift warhead against a moving infectious disease target
    Sheema Mir, Mohammad Ayoub Mir · 2024 · Expert Review of Vaccines
40. Immunizing the Immune: Can We Overcome Influenza’s Most Formidable Challenge?
    Ali H. Ellebedy · 2018 · Vaccines
41. HIV and Messenger RNA Vaccine
    Khizer Khalid, Jaskamal Padda, Anwar Khedr, Dina Ismail, Ujala Zubair, Ola A Al-Ewaidat, Sandeep Padda, Ayden Charlene Cooper, Gutteridge Jean-Charles · 2021 · Cureus
42. mRNA vaccines engage unconventional pathways in CD8+ T cell priming
    Suin Jo, Lijin Li, Chandrani Thakur, Kevin A. Telfer, Hussein Sultan, Ray A. Ohara, Michelle He, Giri Nam, Jing Chen, Feiya Ou et al. · 2026 · Nature
43. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults
    Jenna M. Bartley, Andreia N. Cadar, Dominique E. Martin · 2021 · Immunological Investigations
44. T Cell/B Cell Interactions in the Establishment of Protective Immunity
    Julia Ritzau-Jost, Andreas Hutloff · 2021 · Vaccines
45. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects
    Giorgia Teresa Maniscalco, Valentino Manzo, Anne Lise Ferrara, Alessandro Perrella, Maria Elena Di Battista, Simona Salvatore, Daniela Graziano, Assunta Viola, Gerardino Amato, Ornella Moreggia et al. · 2021 · Multiple Sclerosis and Related Disorders
46. IgA Nephropathy with Gross Hematuria Following COVID-19 mRNA Vaccination
    Yoshihito Nihei, Monami Kishi, Hitoshi Suzuki, Ayako Koizumi, Maiko Yoshida, Sho Hamaguchi, Masako Iwasaki, Hiromitsu Fukuda, Hisatsugu Takahara, Masao Kihara et al. · 2022 · Internal Medicine
47. Debunking mRNA Vaccine Misconceptions—An Overview for Medical Professionals
    Frederick L. Hitti, Drew Weissman · 2021 · The American Journal of Medicine
48. mRNA-based therapies: Preclinical and clinical applications
    Musga Qureischi, Julia Mohr, Estibaliz Arellano-Viera, Sarah E. Knudsen, Farrukh Vohidov, Andoni Garitano-Trojaola · 2022 · International review of cytology
49. Immune responses related to the immunogenicity and reactogenicity of COVID-19 mRNA vaccines
    Takayuki Matsumura, Tomohiro Takano, Yoshimasa Takahashi · 2022 · International Immunology
50. An extended SARS-CoV-2 mRNA vaccine prime-boost interval enhances B cell immunity with limited impact on T cells
    Alexandre Nicolas, Gérémy Sannier, Mathieu Dubé, Manon Nayrac, Alexandra Tauzin, Mark M. Painter, Rishi R. Goel, Mélanie Laporte, Gabrielle Gendron‐Lepage, Halima Medjahed et al. · 2022 · iScience
51. The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2
    Yahya Fahad Jamous, Dalal A Alhomoud · 2023 · Cureus
52. A review of RNA nanoparticles for drug/gene/protein delivery in advanced therapies: Current state and future prospects
    Pegah Vosoughi, Seyed Morteza Naghib, Babak Mikaeeli Kangarshahi, Mohammad Reza Mozafari · 2025 · International Journal of Biological Macromolecules
53. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2
    Changhua Yi, Yongxiang Yi, Junwei Li · 2020 · Virologica Sinica
54. Mixed Amphiphilic Polymeric Nanoparticles of Chitosan, Poly(vinyl alcohol) and Poly(methyl methacrylate) for Intranasal Drug Delivery: A Preliminary In Vivo Study
    Inbar Schlachet, Hen Moshe Halamish, Alejandro Sosnik · 2020 · Molecules
55. Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants
    Sita Awasthi, Lauren M. Hook, Gokul Swaminathan, Tina M. Cairns, Benjamin D. Brooks, Jeffrey S. Smith, Noah T. Ditto, Marian E. Gindy, Andrew J. Bett, Amy S. Espeseth et al. · 2019 · Vaccine
56. Strong influenza-induced T FH generation requires CD4 effectors to recognize antigen locally and receive signals from continuing infection
    Priyadharshini Devarajan, Allen M. Vong, Catherine H. Castonguay, Olivia Kugler‐Umana, Bianca Bautista, Michael C. Jones, Karen A. Kelly, Jingya Xia, Susan L. Swain · 2022 · Proceedings of the National Academy of Sciences
57. Do we miss rare adverse events induced by COVID-19 vaccination?
    Zeinab Mohseni Afshar, Ali Tavakoli Pirzaman, Jackson Jeikai Liang, Akanksha Sharma, Marzieh Pirzadeh, Arefeh Babazadeh, Erfan Hashemi, Niloofar Deravi, Sadaf Abdi, Amirreza Allahgholipour et al. · 2022 · Frontiers in Medicine
58. COVID-19-Induced Myocarditis: Pathophysiological Roles of ACE2 and Toll-like Receptors
    Patrizia Pannucci, Sophie R. Jefferson, Jonathan Hampshire, Samantha Louise Cooper, Stephen J. Hill, Jeanette Woolard · 2023 · International Journal of Molecular Sciences
59. Challenges for the Newborn Following Influenza Virus Infection and Prospects for an Effective Vaccine
    Martha A. Alexander‐Miller · 2020 · Frontiers in Immunology
60. Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV
    Sigrid D’haese, Céline Lacroix, Felipe García, Montserrat Plana, Simona Maria Ruță, Guido L. Vanham, Bernard Verrier, Joeri L. Aerts · 2020 · Journal of Controlled Release
61. Tissue‐Targeted Drug Delivery Strategies to Promote Antigen‐Specific Immune Tolerance
    Yuan Rui, Haleigh B. Eppler, Alexis A. Yanes, Christopher M. Jewell · 2022 · Advanced Healthcare Materials
62. Profile of Katalin Karikó and Drew Weissman: 2023 Nobel laureates in Physiology or Medicine
    Florian Krammer, Peter Palese · 2024 · Proceedings of the National Academy of Sciences
63. Impact of the ileal microbiota on colon cancer
    María Paula Roberti, Conrad Rauber, Guido Kroemer, Laurence Zitvogel · 2021 · Seminars in Cancer Biology
64. RNA–lipid nanoparticles for acute critical illnesses
    Serena Omo‐Lamai, Marco E. Zamora, Bernhard K. Mueller, Jessica C. Casciano, Jacob S. Brenner · 2025 · Nature Reviews Bioengineering
65. mRNA Vaccines: Current Applications and Future Directions
    Jianmei Li, Yixin Liu, Jie Dai, Yang Li, Feng Xiong, Jing Xia, Jing Jin, Yangping Wu, Xingchen Peng · 2025 · MedComm
66. SARS-CoV-2 virus: Vaccines in development
    Qingrui Huang, Jinghua Yan · 2021 · Fundamental Research
67. Nucleoside modifications of in vitro transcribed mRNA to reduce immunogenicity and improve translation of prophylactic and therapeutic antigens
    Mohamad‐Gabriel Alameh, Drew Weissman · 2022 · Elsevier eBooks
68. Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus
    Sarah J. Fidler, Julie Fox, Timothy Tipoe, Stéphanie Longet, Tom Tipton, Movin Abeywickrema, Sandra Adele, Jasmini Alagaratnam, Mohammad Ali, Parvinder K. Aley et al. · 2022 · Clinical Infectious Diseases
69. SARS-CoV-2 Vaccines: Types, Working Principle, and Its Impact on Thrombosis and Gastrointestinal Disorders
    Shubhra Khare, Niharika Niharika, Ajey Singh, Imtiyaz Hussain, N. B. Singh, Subhash C. Singh · 2022 · Applied Biochemistry and Biotechnology
70. Licensed liposomal vaccines and adjuvants in the antigen delivery system
    Yuriy Krasnopolsky, Daria Pylypenko · 2022 · Biotechnologia
71. Historical Advances in Structural and Molecular Biology and How They Impacted Vaccine Development
    Wayne Chester Koff, Rino Rappuoli, Stanley Alan Plotkin · 2023 · Journal of Molecular Biology
72. Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response
    Hye Won Kwak, Hyo‐Jung Park, Hae Li Ko, Hye-Lim Park, Min Ho, Sang‐Myeong Lee, Kyung Won Kang, Rhoon‐Ho Kim, Seung Rok Ryu, Hye Jung Kim et al. · 2019 · Vaccine
73. Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities
    Anna M. Timofeeva, Sergey E. Sedykh, Georgy A. Nevinsky · 2022 · Vaccines
74. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15
    Priyadharshini Devarajan, Allen M. Vong, Catherine H. Castonguay, Noah J. Silverstein, Olivia Kugler‐Umana, Bianca Bautista, Karen A. Kelly, Jeremy Luban, Susan L. Swain · 2023 · Cell Reports
75. IgA nephropathy relapse following COVID-19 vaccination treated with corticosteroid therapy: case report
    Shota Watanabe, Shuling Zheng, Arash Rashidi · 2022 · BMC Nephrology
76. Immune-mediated liver injury following COVID-19 vaccination
    Georgios Schinas, Eleni Polyzou, Vasiliki Dimakopoulou, Stamatia Tsoupra, Charalambos A. Gogos, Karolina Akinosoglou · 2023 · World Journal of Virology
77. COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective
    Cavaillon, Jean-Marc, Osuchowski, Marcin F. · 2021 · Journal of Intensive Medicine
78. Nucleoside-Modified mRNA-Based Influenza Vaccines Circumvent Problems Associated with H3N2 Vaccine Strain Egg Adaptation
    Sigrid Gouma, Colleen Furey, Jefferson José da Silva Santos, Kaela Parkhouse, Madison E. Weirick, Hiromi Muramatsu, Norbert Pardi, Steven H.Y. Fan, Drew Weissman, Scott E. Hensley · 2022 · Journal of Virology
79. Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
    Troy M. Martin, Samuel T. Robinson, Yunda Huang · 2023 · Current Opinion in HIV and AIDS
80. Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models
    Viviane M. Andrade, Igor Maricic, Richa Kalia, Lauren A Jachimowicz, Olivia Bedoya, Daniel W. Kulp, Laurent M. P. F. Humeau, Trevor R.F. Smith · 2023 · Human Vaccines & Immunotherapeutics
81. Nano‐therapeutic strategies to target coronavirus
    Mohd Ahmar Rauf, Munazzah Tasleem, Ketki Bhise, Katyayani Tatiparti, Samaresh Sau, Arun K. Iyer · 2021 · Open Research (University of Surrey)
82. Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers
    Κωνσταντίνα Κοντοπούλου, Alexandra Ainatzoglou, Athina M. Ifantidou, Christos Theodoros Nakas, Georgia Gkounti, Vasilios Adamopoulos, Nikitas Papadopoulos, Georgios Papazisis · 2021 · Journal of Medical Microbiology
83. Delivering the message: How a novel technology enabled the rapid development of effective vaccines
    Lucy Shapiro, Richard M. Losick · 2021 · Cell
84. Messenger ribonucleic acid vaccines against infectious diseases: current concepts and future prospects
    Darin K. Edwards, Andrea Carfı́ · 2022 · Current Opinion in Immunology
85. Predictors of impaired antibody response after SARS‐CoV ‐2 mRNA vaccination in hematopoietic cell transplant recipients: A Japanese multicenter observational study
    Yasuo Mori, Naoyuki Uchida, Takuya Harada, Yuta Katayama, Atsushi Wake, Hiromi Iwasaki, Tetsuya Eto, Satoshi Morishige, Tomoaki Fujisaki, Yoshikiyo Ito et al. · 2022 · American Journal of Hematology
86. Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
    Zhen Qin, Aurélie Bouteau, Christopher Herbst, Botond Z. Igyártó · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
87. Immunology of RNA-based vaccines: The critical interplay between inflammation and expression
    John S. Tregoning, Ziyin Wang, Saranya Sridhar, Robin J. Shattock, Frank DeRosa · 2025 · Molecular Therapy
88. Intranasal hemagglutinin protein boosters induce protective mucosal immunity against influenza A viruses in mice
    Miyu Moriyama, Gisele Regina Rodrigues, Jiping Wang, Radeesha Jayewickreme, Andrew Hudak, Huiping Dong, Robert Homer, Shuangge Ma, Akiko Iwasaki · 2025 · Proceedings of the National Academy of Sciences
89. Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review
    Wubetu Yihunie Belay, Getinet Nibret, Yibeltal Aschale · 2023 · Clinical Pharmacology Advances and Applications
90. Ipsilateral immunization after a prior SARS-CoV-2 mRNA vaccination elicits superior B cell responses compared to contralateral immunization
    Wenxia Jiang, Alexander R. Maldeney, Xue Yuan, Martin J. Richer, Scott E. Renshaw, Wei Luo · 2024 · Cell Reports
91. Semi-enzymatic synthesis of pseudouridine
    Andrew T. Riley, Tristan C. Sanford, Austin M. Woodard, Elliot P. Clerc, Minako Sumita · 2021 · Bioorganic & Medicinal Chemistry Letters
92. Intradermal Delivery of Naked mRNA Vaccines via Iontophoresis
    Mahadi Hasan, Anowara Khatun, Kentaro Kogure · 2023 · Pharmaceutics
93. Engineering ionizable lipids for rapid biodegradation balances mRNA vaccine efficacy and tolerability
    Julien Couture‐Senécal, Grayson Tilstra, Omar F. Khan · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
94. Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
    del Moral-Sánchez, Iván, Wee, Edmund G., Xian, Yuejiao, Lee, Wen-Hsin, Allen, Joel D., Torrents de la Peña, Alba, Fróes Rocha, Rebeca, Ferguson, James, León, André N., Koekkoek, Sylvie et al. · 2024 · npj Vaccines
95. Increasing polycation hydrophobicity in mRNA polyplex vaccines enhances the efficacy of humoral and cellular immunity induction
    Nan Qiao, Mao Hori, Mitsuru Naito, Heemin Chang, Satomi Ogura, Mika Suzuki, Tsuyoshi Kimura, Shigeto Fukushima, Hyun Jin Kim, Satoshi Uchida et al. · 2025 · Biomaterials
96. Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
    Alessio Alesci, Marco Gitto, Magdalena Kotańska, Patrizia Lo Cascio, Anthea Miller, Noemi Nicosia, Angelo Fumia, Simona Pergolizzi · 2022 · Human Immunology
97. Potent cancer therapy by liposome microstructure tailoring with active-to-passive targeting and shell-to-core thermosensitive features
    Mengxin Zhao, Xiaodong Zhu, Bailing Li, Chenyang Yan, Cong Wu, Lei He, Jingyi Cao, Fanglin Lu, Han Chen, Wei Li · 2024 · Materials Today Bio
98. Implementation of mRNA–Lipid Nanoparticle Technology in Atlantic Salmon (Salmo salar)
    Lars Ole Sti Dahl, Sjoerd Hak, Stine Braaen, Alicja Molska, Francesca Rodà, Jérémie Parot, Øystein Wessel, Johanna Hol Fosse, Håvard Bjørgen, Sven Even Borgos et al. · 2024 · Vaccines
99. Nucleic acid vaccines: innovations, efficacy, and applications in at-risk populations
    Emily Konopka, Arden O. Edgerton, Michele A. Kutzler · 2025 · Frontiers in Immunology
100. Prime-boost vaccination regimens with INO-4800 and INO-4802 augment and broaden immune responses against SARS-CoV-2 in nonhuman primates
     Jewell N. Walters, Blake Schouest, Ami R. Patel, Emma L. Reuschel, Katherine Schultheis, Elizabeth M. Parzych, Igor Maricic, Ebony Nicole Gary, Mansi Purwar, Viviane M. Andrade et al. · 2022 · Vaccine